Compass Therapeutics' tovecimig fails overall survival goal in biliary tract cancer trial
Updated
Updated · MarketWatch · Apr 27
Compass Therapeutics' tovecimig fails overall survival goal in biliary tract cancer trial
8 articles · Updated · MarketWatch · Apr 27
The trial showed a 56% reduction in disease progression risk, but 54% of control patients crossed over to the treatment arm.
While tovecimig improved progression-free survival significantly, the high crossover rate rendered overall survival data uninterpretable, leading to a 23% drop in Compass shares.
Biliary tract cancer affects the bile ducts or gallbladder, and Compass Therapeutics' stock had already declined 6% this year before the latest results.
A drug cut cancer progression by 56%, so why did the company's stock plummet 23%?
Why are investors ignoring a huge survival benefit seen in patients who switched treatments?
How will the FDA's new AI inspection tools affect the approval path for Compass's drug?
Did an ethical trial design unintentionally mask a life-saving cancer drug's true potential?
Is the 'gold standard' for approving cancer drugs becoming an outdated and impossible goal?